Serotonin receptor signaling and regulation via β-arrestins

References

• Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SG, Caron MG and Roth BL. 2009. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci 29:7124–7136.
   PubMed Web of Science ®Google Scholar
• Aghajanian GK and Marek GJ. 1999. Serotonin and hallucinogens. Neuropsychopharmacology 21:16S–23S.
   PubMed Web of Science ®Google Scholar
• Ahn S, Nelson CD, Garrison TR, Miller WE and Lefkowitz RJ. 2003. Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc Natl Acad Sci USA 100:1740–1744.
   PubMed Web of Science ®Google Scholar
• Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, Snyder SH, Caron MG and Lefkowitz RJ. 1992. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem 267:17882–17890.
   PubMed Web of Science ®Google Scholar
• Barak LS, Ferguson SS, Zhang J and Caron MG. 1997. A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem 272:27497–27500.
   PubMed Web of Science ®Google Scholar
• Barthet G, Gaven F, Framery B, Shinjo K, Nakamura T, Claeysen S, Bockaert J and Dumuis A. 2005. Uncoupling and endocytosis of 5-b hydroxytryptamine 4 receptors. Distinct molecular events with different GRK2 requirements. J Biol Chem 280:27924–27934.
   PubMed Web of Science ®Google Scholar
• Barthet G, Framery B, Gaven F, Pellissier L, Reiter E, Claeysen S, Bockaert J and Dumuis A. 2007. 5-hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling. Mol Biol Cell 18:1979–1991.
   PubMed Web of Science ®Google Scholar
• Barthet G, Carrat G, Cassier E, Barker B, Gaven F, Pillot M, Framery B, Pellissier LP, Augier J, Kang DS, Claeysen S, Reiter E, Baneres JL, Benovic JL, Marin P, Bockaert J and Dumuis A. 2009. Beta-arrestin1 phosphorylation by GRK5 regulates G protein-independent 5-HT4 receptor signalling. EMBO J 28:2706–2718.
   PubMed Web of Science ®Google Scholar
• Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR and Caron MG. 2005. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261–273.
   PubMed Web of Science ®Google Scholar
• Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR and Caron MG. 2008. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125–136.
   PubMed Web of Science ®Google Scholar
• Berg KA, Clarke WP, Cunningham KA and Spampinato U. 2008. Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications. Neuropharmacology 55:969–976.
   PubMed Web of Science ®Google Scholar
• Berry SA, Shah MC, Khan N and Roth BL. 1996. Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Mol Pharmacol 50:306–313.
   PubMed Web of Science ®Google Scholar
• Bhatnagar A, Willins DL, Gray JA, Woods J, Benovic JL and Roth BL. 2001. The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J Biol Chem 276:8269–8277.
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Sankar S and Panicker MM. 2010. Differences in the C-terminus contribute to variations in trafficking between rat and human 5-HT(2A) receptor isoforms: identification of a primate-specific tripeptide ASK motif that confers GRK-2 and beta arrestin-2 interactions. J Neurochem 112:723–732.
   PubMed Web of Science ®Google Scholar
• Blondel O, Gastineau M, Dahmoune Y, Langlois M and Fischmeister R. 1998. Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J Neurochem 70:2252–2261.
   PubMed Web of Science ®Google Scholar
• Bockaert J, Claeysen S, Compan V and Dumuis A. 2004. 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord 3:39–51.
   PubMedGoogle Scholar
• Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG and Lin FT. 1999. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495–2498.
   PubMed Web of Science ®Google Scholar
• Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ and Caron MG. 2000. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720–723.
   PubMed Web of Science ®Google Scholar
• Bohn LM, Lefkowitz RJ and Caron MG. 2002. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 22:10494–10500.
   PubMed Web of Science ®Google Scholar
• Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG and Barak LS. 2004. Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 66:106–112.
   PubMed Web of Science ®Google Scholar
• Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E and Emeson RB. 1997. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387:303–308.
   PubMed Web of Science ®Google Scholar
• Claeysen S, Faye P, Sebben M, Taviaux S, Bockaert J and Dumuis A. 1998. 5-HT4 receptors: cloning and expression of new splice variants. Ann NY Acad Sci 861, 49–56.
   PubMed Web of Science ®Google Scholar
• Claeysen S, Sebben M, Becamel C, Bockaert J and Dumuis A. 1999. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol 55:910–920.
   PubMed Web of Science ®Google Scholar
• Claeysen S, Sebben M, Becamel C, Parmentier ML, Dumuis A and Bockaert J. 2001. Constitutively active mutants of 5-HT4 receptors are they in unique active states? EMBO Rep 2:61–67.
   PubMed Web of Science ®Google Scholar
• Conn PJ and Sanders-Bush E. 1984. Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology 23:993–996.
   PubMed Web of Science ®Google Scholar
• Conn PJ and Sanders-Bush E. 1986. Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J Neurosci 6:3669–3675.
   PubMed Web of Science ®Google Scholar
• Conner DA, Mathier MA, Mortensen RM, Christe M, Vatner SF, Seidman CE and Seidman JG. 1997. beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. Circ Res 81:1021–1026.
   PubMed Web of Science ®Google Scholar
• Corne SJ and Pickering RW. 1967. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia 11:65–78.
   PubMed Web of Science ®Google Scholar
• Corne SJ, Pickering RW and Warner BT. 1963. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol Chemother 20:106–120.
   PubMed Web of Science ®Google Scholar
• Cornea-Hebert V, Riad M, Wu C, Singh SK and Descarries L. 1999. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 409:187–209.
   PubMed Web of Science ®Google Scholar
• Cornea-Hebert V, Watkins KC, Roth BL, Kroeze WK, Gaudreau P, Leclerc N and Descarries L. 2002. Similar ultrastructural distribution of the 5-HT(2A) serotonin receptor and microtubule-associated protein MAP1A in cortical dendrites of adult rat. Neuroscience 113:23–35.
   PubMed Web of Science ®Google Scholar
• Daaka Y, Luttrell LM, Ahn S, Della Rocca GJ, Ferguson SS, Caron MG and Lefkowitz RJ. 1998. Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 273:685–688.
   PubMed Web of Science ®Google Scholar
• DeWire SM, Ahn S, Lefkowitz RJ and Shenoy SK. 2007. Beta-arrestins and cell signaling. Annu Rev Physiol 69:483–510.
   PubMed Web of Science ®Google Scholar
• Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK and Lefkowitz RJ. 2008. beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 283:5669–5676.
   PubMed Web of Science ®Google Scholar
• Dumuis A, Bouhelal R, Sebben M, Cory R and Bockaert J. 1988. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol 34:880–887.
   PubMed Web of Science ®Google Scholar
• Ferguson SS. 2001. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1–24.
   PubMed Web of Science ®Google Scholar
• Ferguson SS, Downey WE, 3rd Colapietro, AM, Barak LS, Menard L and Caron MG. 1996. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271:363–366.
   PubMed Web of Science ®Google Scholar
• Gelber EI, Kroeze WK, Willins DL, Gray JA, Sinar CA, Hyde EG, Gurevich V, Benovic J and Roth BL. 1999. Structure and function of the third intracellular loop of the 5-hydroxytryptamine2A receptor: the third intracellular loop is alpha-helical and binds purified arrestins. J Neurochem 72:2206–2214.
   PubMed Web of Science ®Google Scholar
• Giorgetti M and Tecott LH. 2004. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 488:1–9.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC and Gingrich JA. 2007. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53:439–452.
   PubMed Web of Science ®Google Scholar
• Goodman OB, Jr Krupnick, JG, Santini F, Gurevich VV, Penn RB, Gagnon AW, Keen JH and Benovic JL. 1996. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 383:447–450.
   PubMed Web of Science ®Google Scholar
• Gray JA and Roth BL. 2001. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56:441–451.
   PubMed Web of Science ®Google Scholar
• Gray JA, Sheffler DJ, Bhatnagar A, Woods JA, Hufeisen SJ, Benovic JL and Roth BL. 2001. Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells. Mol Pharmacol 60:1020–1030.
   PubMed Web of Science ®Google Scholar
• Gray JA, Bhatnagar A, Gurevich VV and Roth BL. 2003. The interaction of a constitutively active arrestin with the arrestin-insensitive 5-HT(2A) receptor induces agonist-independent internalization. Mol Pharmacol 63:961–972.
   PubMed Web of Science ®Google Scholar
• Gray-Keller MP, Detwiler PB, Benovic JL and Gurevich VV. 1997. Arrestin with a single amino acid substitution quenches light-activated rhodopsin in a phosphorylation-independent fashion. Biochemistry 36:7058–7063.
   PubMed Web of Science ®Google Scholar
• Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE and Bohn LM. 2007. An opioid agonist that does not induce micro-opioid receptor–arrestin interactions or receptor internalization. Mol Pharmacol 71:549–557.
   PubMed Web of Science ®Google Scholar
• Gurevich VV and Gurevich EV. 2006. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther 110:465–502.
   PubMed Web of Science ®Google Scholar
• Gurevich VV, Dion SB, Onorato JJ, Ptasienski J, Kim CM, Sterne-Marr R, Hosey MM and Benovic JL. 1995. Arrestin interactions with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, beta 2-adrenergic, and m2 muscarinic cholinergic receptors. J Biol Chem 270:720–731.
   PubMed Web of Science ®Google Scholar
• Gurevich EV, Benovic JL and Gurevich VV. 2002. Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development. Neuroscience 109:421–436.
   PubMed Web of Science ®Google Scholar
• Hamdan FF, Audet M, Garneau P, Pelletier J and Bouvier M. 2005. High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J Biomol Screen 10:463–475.
   PubMed Web of Science ®Google Scholar
• Hanley NR and Hensler JG. 2002. Mechanisms of ligand-induced desensitization of the 5-hydroxytryptamine(2A) receptor. J Pharmacol Exp Ther 300:468–477.
   PubMed Web of Science ®Google Scholar
• Ivins KJ and Molinoff PB. 1991. Desensitization and down-regulation of 5-HT2 receptors in P11 cells. J Pharmacol Exp Ther 259:423–429.
   PubMed Web of Science ®Google Scholar
• Iwamoto K, Bundo M and Kato T. 2009. Serotonin receptor 2C and mental disorders: genetic, expression and RNA editing studies. RNA Biol 6:248–253.
   PubMed Web of Science ®Google Scholar
• Joubert L, Hanson B, Barthet G, Sebben M, Claeysen S, Hong W, Marin P, Dumuis A and Bockaert J. 2004. New sorting nexin (SNX27) and NHERF specifically interact with the 5-HT4a receptor splice variant: roles in receptor targeting. J Cell Sci 117:5367–5379.
   PubMed Web of Science ®Google Scholar
• Kenakin T. 1995. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232–238.
   PubMed Web of Science ®Google Scholar
• Kim HS. 2009. 5-Hydroxytryptamine4 receptor agonists and colonic motility. J Smooth Muscle Res 45:25–29.
   PubMedGoogle Scholar
• Kim YM and Benovic JL. 2002. Differential roles of arrestin-2 interaction with clathrin and adaptor protein 2 in G protein-coupled receptor trafficking. J Biol Chem 277:30760–30708.
   PubMed Web of Science ®Google Scholar
• Kobilka BK and Deupi X. 2007. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28:397–406.
   PubMed Web of Science ®Google Scholar
• Kohout TA, Lin FS, Perry SJ, Conner DA and Lefkowitz RJ. 2001. beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci USA 98:1601–1606.
   PubMed Web of Science ®Google Scholar
• Kovacs JJ, Hara MR, Davenport CL, Kim J and Lefkowitz RJ. 2009. Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell 17:443–458.
   PubMed Web of Science ®Google Scholar
• Kovoor A, Celver J, Abdryashitov RI, Chavkin C and Gurevich VV. 1999. Targeted construction of phosphorylation-independent beta-arrestin mutants with constitutive activity in cells. J Biol Chem 274:6831–6834.
   PubMed Web of Science ®Google Scholar
• Krupnick JG, Santini F, Gagnon AW, Keen JH and Benovic JL. 1997. Modulation of the arrestin-clathrin interaction in cells. Characterization of beta-arrestin dominant-negative mutants. J Biol Chem 272:32507–32512.
   PubMed Web of Science ®Google Scholar
• Labasque M, Reiter E, Becamel C, Bockaert J and Marin P. 2008. Physical interaction of calmodulin with the 5-hydroxytryptamine2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling. Mol Biol Cell 19:4640–4650.
   PubMed Web of Science ®Google Scholar
• Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SS, Caron MG and Barak LS. 1999. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci USA 96:3712–3717.
   PubMed Web of Science ®Google Scholar
• Lefkowitz RJ and Shenoy SK. 2005. Transduction of receptor signals by beta-arrestins. Science 308:512–517.
   PubMed Web of Science ®Google Scholar
• Leysen JE. 2004. 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 3:11–26.
   PubMedGoogle Scholar
• Liu Y, Emeson RB and Samuel CE. 1999. Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1. J Biol Chem 274:18351–18358.
   PubMed Web of Science ®Google Scholar
• Luttrell LM and Lefkowitz RJ. 2002. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455–465.
   PubMed Web of Science ®Google Scholar
• Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG and Lefkowitz RJ. 1999. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283:655–661.
   PubMed Web of Science ®Google Scholar
• Maes M and Meltzer HY. 1995. The serotonin hypothesis of major depression. In: Bloom FE and Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press.
   Google Scholar
• Marion S, Oakley RH, Kim KM, Caron MG and Barak LS. 2006. A beta-arrestin binding determinant common to the second intracellular loops of rhodopsin family G protein-coupled receptors. J Biol Chem 281:2932–2938.
   PubMed Web of Science ®Google Scholar
• Marion S, Weiner DM and Caron MG. 2004. RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol Chem 279:2945.
   PubMed Web of Science ®Google Scholar
• McDonald PH and Bohn LM. 2010. Seeking ligand bias: assessing GPCR coupling to beta-arrestins for drug discovery. Drug Discovery Today (in press).
   Google Scholar
• McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ and Lefkowitz RJ. 2000. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290:1574–1577.
   PubMed Web of Science ®Google Scholar
• Meltzer HY. 2002. Mechanism of action of atypical antipsychotic drugs. In: Davis KL, Charney D, Coyle JT and Nemeroff C. (eds) Neuropsychopharmacology: The Fifth Generation of Progress. New York: Raven Press.
   Google Scholar
• Menard L, Ferguson SS, Zhang J, Lin FT, Lefkowitz RJ, Caron MG and Barak LS. 1997. Synergistic regulation of beta2-adrenergic receptor sequestration: intracellular complement of beta-adrenergic receptor kinase and beta-arrestin determine kinetics of internalization. Mol Pharmacol 51:800–808.
   PubMed Web of Science ®Google Scholar
• Millan MJ. 2005. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60:441–460.
   PubMed Web of Science ®Google Scholar
• Mnie-Filali O, Amraei MG, Benmbarek S, Archer-Lahlou E, Penas-Cazorla R, Vilaro MT, Boye SM and Pineyro G. 2010. Serotonin 4 receptor (5-HT4R) internalization is isoform-specific: effects of 5-HT and RS67333 on isoforms A and B. Cell Signal 22:501–509.
   PubMed Web of Science ®Google Scholar
• Nichols DE. 2004. Hallucinogens. Pharmacol Ther 101:131–181.
   PubMed Web of Science ®Google Scholar
• Niswender CM, Sanders-Bush E and Emeson RB. 1998. Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann NY Acad Sci 861:38–48.
   PubMed Web of Science ®Google Scholar
• Oakley RH, Laporte SA, Holt JA, Caron MG and Barak LS. 2000. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275:17201–17210.
   PubMed Web of Science ®Google Scholar
• Orsini MJ and Benovic JL. 1998. Characterization of dominant negative arrestins that inhibit beta2-adrenergic receptor internalization by distinct mechanisms. J Biol Chem 273:34616–34622.
   PubMed Web of Science ®Google Scholar
• Ouadid H, Seguin J, Dumuis A, Bockaert J and Nargeot J. 1992. Serotonin increases calcium current in human atrial myocytes via the newly described 5-hydroxytryptamine4 receptors. Mol Pharmacol 41, 346–351.
   PubMed Web of Science ®Google Scholar
• Pierce KL and Lefkowitz RJ. 2001. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2:727–733.
   PubMed Web of Science ®Google Scholar
• Pieri L, Keller HH, Burkard W and Da Prada M. 1978. Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272:278–280.
   PubMed Web of Science ®Google Scholar
• Ponimaskin E, Dumuis A, Gaven F, Barthet G, Heine M, Glebov K, Richter DW and Oppermann M. 2005. Palmitoylation of the 5-hydroxytryptamine4a receptor regulates receptor phosphorylation, desensitization, and beta-arrestin-mediated endocytosis. Mol Pharmacol 67:1434–1443.
   PubMed Web of Science ®Google Scholar
• Roth BL and Meltzer HY. 1995. The role of serotonin in schizophrenia. In: Bloom FE and Kupfer DJ. (eds) Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press.
   Google Scholar
• Roth BL, Nakaki T, Chuang DM and Costa E. 1984. Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover. Neuropharmacology 23:1223–1225.
   PubMed Web of Science ®Google Scholar
• Roth BL, Palvimaki EP, Berry S, Khan N, Sachs N, Uluer A and Choudhary MS. 1995. 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther 275:1638–1646.
   PubMed Web of Science ®Google Scholar
• Roth BL, Berry SA, Kroeze WK, Willins DL and Kristiansen K. 1998. Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation. Crit Rev Neurobiol 12:319–338.
   PubMedGoogle Scholar
• Schmid CL and Bohn LM. 2009. Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther 121:285–293.
   PubMed Web of Science ®Google Scholar
• Schmid CL and Bohn LM. 2010. Serotonin, but not N-Methyltryptamines, activates the Serotonin 2A Receptor via a barrestin2/Src/AKT signaling complex in vivo. J Neurosci 30:13513–13524.
   PubMed Web of Science ®Google Scholar
• Schmid CL, Raehal KM and Bohn LM. 2008. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA 105:1079–1084.
   PubMed Web of Science ®Google Scholar
• Shenoy SK and Lefkowitz RJ. 2003. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 375:503–515.
   PubMed Web of Science ®Google Scholar
• Stalheim L, Ding Y, Gullapalli A, Paing MM, Wolfe BL, Morris DR and Trejo J. 2005. Multiple independent functions of arrestins in the regulation of protease-activated receptor-2 signaling and trafficking. Mol Pharmacol 67:78–87.
   PubMed Web of Science ®Google Scholar
• Urban JD, Clarke WP, Von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M and Mailman RB. 2007. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1–13.
   PubMed Web of Science ®Google Scholar
• von Degenfeld G, Wehrman TS, Hammer MM and Blau HM. 2007. A universal technology for monitoring G-protein-coupled receptor activation in vitro and noninvasively in live animals. Faseb J 21:3819–3826.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhao J, Brady AE, Feng J, Allen PB, Lefkowitz RJ, Greengard P and Limbird LE. 2004. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 304:1940–1944.
   PubMed Web of Science ®Google Scholar
• Werry TD, Gregory KJ, Sexton PM and Christopoulos A. 2005. Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J Neurochem 93:1603–1615.
   PubMed Web of Science ®Google Scholar
• Werry TD, Christopoulos A and Sexton PM. 2006. Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. Curr Pharm Des 12:1683–1702.
   PubMed Web of Science ®Google Scholar
• Willins DL, Deutch AY and Roth BL. 1997. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27:79–82.
   PubMed Web of Science ®Google Scholar
• Xia Z, Hufeisen SJ, Gray JA and Roth BL. 2003. The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience 122:907–920.
   PubMed Web of Science ®Google Scholar
• Yuen EY, Jiang Q, Chen P, Feng J and Yan Z. 2008. Activation of 5-HT2A/C receptors counteracts 5-HT1A regulation of n-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex. J Biol Chem 283:17194–17204.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Al-Saady N and Camm AJ. 2003. 5-hydroxytryptamine and atrial fibrillation: how significant is this piece in the puzzle? J Cardiovasc Electrophysiol 14:209–214.
   PubMed Web of Science ®Google Scholar
• Zhang J, Barak LS, Winkler KE, Caron MG and Ferguson SS. 1997. A central role for beta-arrestins and clathrin-coated vesicle-mediated endocytosis in beta2-adrenergic receptor resensitization. Differential regulation of receptor resensitization in two distinct cell types. J Biol Chem 272:27005–27014.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY and Caron MG. 1998. Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci USA 95:7157–7162.
   PubMed Web of Science ®Google Scholar